PreserVision AREDS3 Side Effects: What Changed From AREDS2 (and Why)

Written by Dr. Louis Michaelos, Ophthalmologist & Founder, MacuRest | Last reviewed August 2026

TL;DR: PreserVision AREDS3, launched in February 2026, cut its daily zinc dose from 80 mg (the original AREDS2 level) down to 25 mg. That change wasn't cosmetic — high-dose zinc has long been one of the most commonly reported reasons patients stop taking AREDS2 supplements, with upset stomach, nausea, and cramping showing up repeatedly in user reports. Bausch + Lomb's own product materials cite AREDS2 trial data showing no meaningful outcome difference between the 80 mg and 25 mg zinc doses as the rationale for the change. MacuRest was formulated at 25 mg zinc from day one, for the same reason.

Why AREDS2's High Zinc Dose Became a Problem

The original AREDS2 formula, still sold today as PreserVision AREDS 2, delivers 80 mg of zinc oxide per day. That dose was carried over from the earliest AREDS trial in the 1990s and has stayed in place for decades. It's also, by a wide margin, the ingredient patients complain about most.

Across pharmacy review sites and patient forums, the pattern is consistent: people describe nausea, stomach cramping, and general GI discomfort after starting AREDS2, often within the first few days. Some find it improves when the supplement is taken with food or split into two smaller doses; others stop taking it altogether. Because AMD supplementation only works if it's taken consistently over years, a supplement that's hard to tolerate is a real clinical problem, not just an inconvenience.

What AREDS3 Actually Changed

When Bausch + Lomb launched PreserVision AREDS3 in February 2026, the headline feature was the addition of an 8-part B-vitamin complex. But the quieter — and arguably more consequential — change was cutting the zinc dose from 80 mg to 25 mg per day. The company's own product documentation points to findings from the original AREDS2 trial itself: statistically, there was no meaningful difference in AMD outcomes between the high 80 mg zinc dose and a lower 25 mg dose. In other words, the extra zinc wasn't buying patients extra protection — just extra side effects for some of them.

Does the Lower Dose Actually Mean Fewer Side Effects?

Here's where it's important to be precise: AREDS3 is still new enough that there isn't a large independent body of patient-reported side-effect data on the 25 mg formula specifically the way there is for AREDS2. What we do have is early retail feedback — AREDS3 reviews on major retail sites have skewed positive so far, with several reviewers specifically describing the softgels as easy on the stomach compared to their prior AREDS2 experience. That's a reasonable early signal, and it lines up with what you'd expect physiologically: zinc-related GI irritation is generally dose-dependent, so a lower dose should, on average, be gentler. But "should be gentler" isn't the same as a clinical trial confirming it, and individual tolerance still varies.

Where MacuRest Fits In

MacuRest was built around a 25 mg zinc dose from the start, before AREDS3 existed, based on the same AREDS2 sub-analysis data Bausch + Lomb later cited. MacuRest also includes a B-complex, similar in spirit to AREDS3's approach, plus 5 mg of melatonin for evening use, which no PreserVision formula includes. If GI tolerability is what's pushing you to consider switching off AREDS2, it's worth knowing that lower-zinc options other than AREDS3 already exist. For the full nutrient-by-nutrient breakdown, see our AREDS2 vs AREDS3 comparison.

Frequently Asked Questions

Does PreserVision AREDS3 have fewer side effects than AREDS2?

Early retail reviews suggest better GI tolerability, and the lower 25 mg zinc dose supports that physiologically, but there isn't yet a large independent body of patient-reported data specific to AREDS3. If you've struggled with AREDS2 in the past, a lower-zinc option is worth discussing with your ophthalmologist.

Why did AREDS2 use 80 mg of zinc in the first place?

That dose came from the original 1990s AREDS trial and was carried forward into AREDS2. A later sub-analysis of the AREDS2 trial data found no statistically significant outcome difference between the 80 mg and 25 mg zinc doses, which is the rationale AREDS3 and other lower-zinc formulas now cite.

Is a lower zinc dose still effective for AMD?

According to the AREDS2 trial's own sub-analysis, yes — the 25 mg dose performed comparably to 80 mg. The AAO-recommended standard remains the full AREDS2 formula, but the zinc-dose question specifically has reasonable trial-backed support either way.

What should I do if AREDS2 upsets my stomach?

Taking it with food or splitting the dose can help some people. If discomfort continues, talk to your ophthalmologist about lower-zinc alternatives rather than stopping supplementation altogether, since consistent long-term use is what the underlying research is based on.

This article is for informational purposes only and does not constitute medical advice. Patients with AMD should work with a licensed ophthalmologist before switching supplements or changing dosage. Last updated August 2026.